SpringWorks Therapeutics — Corporate Update (November 2023)
24 slides from SpringWorks Therapeutics's corporate update, Nov 28, 2023
Slide 1: FDA Approval Call November 27, 2023
FDA Approval Call November 27, 2023
Slide 2: Forward-looking statements note
2 Note: Unless otherwise indicated, the information presented herein is as of November 27, 2023. This presentation may contain “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, relating to our business, operations, and financial co
Slide 3: Today's Speakers and Agenda
3 Today’s Speakers and Agenda Sections Presenter Opening Remarks Saqib Islam Chief Executive Officer U.S. Prescribing Information Jim Cassidy, MD, PhD Chief Medical Officer U.S. Launch Plans for OGSIVEO Bhavesh Ashar Chief Commercial Officer Closing Remarks Saqib Islam Chief Executive Officer Q&A Al
Slide 4: Opening Remarks
Opening Remarks Saqib Islam Chief Executive Officer
Slide 5: First and Only FDA Approved Therapy for Adult Patients With Desmoid Tumors
5 First and Only FDA Approved Therapy for Adult Patients With Desmoid Tumors 5
Slide 6: Desmoid Tumor Patients Have Been Waiting for a Safe and Effective Therapy
6 Desmoid Tumor Patients Have Been Waiting for a Safe and Effective Therapy Aggressive, invasive and highly debilitating soft - tissue tumors Can cause severe and chronic pain, loss of physical functioning and disfigurement Off - label systemic treatments are often poorly tolerated with limited effi
Slide 7: OGSIVEO Can Address the Needs of Desmoid Tumor Patients at All Stages
7 ~1,000 - 1,650 new patients diagnosed annually Incidence of 3 – 5 per million per year (1 - 3) with over 90% of patients receiving active intervention over the course of their disease OGSIVEO Can Address the Needs of Desmoid Tumor Patients at All Stages of Treatment Sources: SWTX Primary Research;
Slide 8: Delivering the First FDA-Approved Therapy for Patients With Desmoid Tumors
8 Broad label that enables patients at every stage of their treatment journey to be eligible for OGSIVEO Delivering the First FDA - Approved Therapy for Patients With Desmoid Tumors Joe Andrea Dana Significantly reduces disease progression and tumor size while addressing pain and other debilitating
Slide 9: U.S. Prescribing Information
U.S. Prescribing Information Jim Cassidy, MD, PhD Chief Medical Officer
Slide 10: OGSIVEO U.S. Prescribing Information Overview
10 OGSIVEO U.S. Prescribing Information Overview Full prescribing information is available at www.OGSIVEO.com. FIRST AND ONLY FDA - APPROVED THERAPY FOR DESMOID TUMOR PATIENTS INDICATION OGSIVEO is a gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require s
Slide 11: Efficacy Summary From OGSIVEO Prescribing Information
11 Efficacy Summary From OGSIVEO Prescribing Information Full prescribing information is available at www.OGSIVEO.com. Note: CI: confidence interval; ORR: objective response rate; CR: complete response; PR: partial response; NR: not reached. a) Assessed by blinded independent central review. b) Obta
Slide 12: Safety Summary From OGSIVEO Prescribing Information
12 Safety Summary From OGSIVEO Prescribing Information Full prescribing information is available at www.OGSIVEO.com. (1) Reported in over 15% of patients. Warnings and Precautions ▪ Diarrhea, ovarian toxicity, hepatotoxicity, non - melanoma skin cancers, electrolyte abnormalities, embryo - fetal tox
Slide 13: U.S. Launch Plans for OGSIVEO
U.S. Launch Plans for OGSIVEO Bhavesh Ashar Chief Commercial Officer
Slide 14: Foundation in Place for OGSIVEO to Become the Standard of Care
14 Foundation in Place for OGSIVEO to Become the Standard of Care Source: SWTX Primary Research, 2Q22; aided awareness. Motivated patient population Favorable shifts in market dynamics First and only approved therapy Physician enthusiasm and familiarity SARC Center participation in DeFi trial Stated
Slide 15: Strategic Imperatives For OGSIVEO Launch
15 Strategic Imperatives For OGSIVEO Launch EXPAND Educate physicians and patients to broaden the role of systemic therapy ADOPT Position OGSIVEO as first or next systemic treatment and standard of care SUPPORT Provide comprehensive patient support to help maximize patient access and adherence LEAD
Slide 16: Targeted Launch Strategy With a Highly Experienced Field Team
16 ‒ Regional Business Managers ‒ Thought Leader Liaisons ‒ Field Access Managers ‒ Nurse Advocates ‒ National Account Directors ‒ Medical Science Liaisons 35 Territory Business Managers supported by: Targeted Launch Strategy With a Highly Experienced Field Team Position OGSIVEO as first or next sys
Slide 17: Transformative Clinical Benefit to Patients
17 Transformative Clinical Benefit to Patients First and Only FDA - Approved Therapy Aggressive and Debilitating Rare Disease Ongoing Commitment to the Desmoid Tumor Community A Compelling Value Proposition for Stakeholders Our objective is that every appropriate patient who can benefit from OGSIVEO
Slide 18: Robust and Tailored Patient Support and Access Program
18 Robust and Tailored Patient Support and Access Program Financial Assistance Financial support for eligible patients, including co - pay program and Patient Assistance Program Coverage and Access Support Resources to facilitate reimbursement and timely and appropriate access to OGSIVEO Personalize
Slide 19: Patient testimonial: Stephanie
My tumor grew while on oral chemotherapy. I was switched to IV chemo, which shrank my tumor, but I had such bad side - effects that I had to take a break. My latest MRI shows that my tumor is stable, but it is pushing on my tailbone and causing excruciating pain. I am taking heavy duty pain medicati
Slide 20: Closing Remarks
Closing Remarks Saqib Islam Chief Executive Officer
Slide 21: Rapidly Transitioning Into a Commercial-Stage Company
21 21 Rapidly Transitioning Into a Commercial - Stage Company With Multiple Potential Value Drivers U.S. approval of OGSIVEO represents the first and only approved treatment for desmoid tumors, with data supporting a potentially practice - changing therapeutic profile for patients and meaningful com
Slide 22: Thank You
PATIENTS HAVE BEEN WAITING FOR ANSWERS. T’S GO Thank You &Y SpringWorks: THERAPEUTICS
Slide 23: Q&A
23 Badreddin Edris, PhD Chief Operating Officer Jim Cassidy, MD, PhD Chief Medical Officer Bhavesh Ashar Chief Commercial Officer Q&A Saqib Islam Chief Executive Officer
Slide 24: SpringWorks Therapeutics
2 SpringWorks' THERAPEUTICS
SpringWorks Therapeutics — Corporate Update (November 2023) on 6ix